

## INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/EP 03/05753

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/7088 A61K31/522 A61K31/675 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BAIREY OSNAT ET AL: "Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide." AMERICAN JOURNAL OF HEMATOLOGY, vol. 69, no. 4, April 2002 (2002-04), pages 281-284, XP008022853 April, 2002 ISSN: 0361-8609	1-3, 7-10, 15, 18, 27, 28
Y	page 282, left-hand column page 283, left-hand column, paragraph 2 page 284, left-hand column, line 1 --- -/--	1-28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

2 October 2003

Date of mailing of the international search report

20/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Beranová, P

BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

 Intern Application No  
 PCT/EP 03/05753

## C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RICHARDSON P G ET AL: "Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population." BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 853a XP008022856 43rd Annual Meeting of the American Society of Hematology, Part 1; Orlando, Florida, USA; December 07-11, 2001, November 16, 2001 ISSN: 0006-4971	1-3,5, 7-9,15, 18,19,27
Y	* abstract *	1-28
X	--- MIRANDA N ET AL: "Treatment of hepatic veno-occlusive disease (VOD) with defibrotide: Results in 5 stem cell transplant recipients." BLOOD, vol. 94, no. 10 SUPPL. 1 PART 2, 15 November 1999 (1999-11-15), page 359b XP008022854 Forty-first Annual Meeting of the American Society of Hematology; New Orleans, Louisiana, USA; December 3-7, 1999 ISSN: 0006-4971	1-3,5,7, 18,19, 27,28
Y	* abstract *	1-28
X	--- SHAW B E ET AL: "The use of defibrotide in the management of vascular endothelial complications (VOD/HUS/TTP) of stem cell transplantation." BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), page 608a XP008022855 Forty-first Annual Meeting of the American Society of Hematology; New Orleans, Louisiana, USA; December 3-7, 1999 ISSN: 0006-4971 * abstract * --- -/--	1-3,7, 15,16, 18,27,28

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/05753

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SAYER H G ET AL: "Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation: Successful treatment with high-dose methylprednisolone and defibrotide."</p> <p>JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol. 128, no. 3, March 2002 (2002-03), pages 148-152, XP002256487 ISSN: 0171-5216 page 149, left-hand column -right-hand column page 150, left-hand column, paragraph 1</p>	1-3, 5-10,15, 16,27
X	<p>MAISANO ROBERTO ET AL: "Defibrotide in the prevention of venous irritation by vinorelbine administration."</p> <p>ANTICANCER RESEARCH, vol. 17, no. 4A, 1997, pages 2775-2777, XP008022875 ISSN: 0250-7005</p>	1-3,7-9, 27,28
Y	<p>* page 2775, "Patients and Methods" *</p> <p>page 2776, right-hand column, paragraph 2</p>	1-28
X	<p>RICHARDSON PAUL G ET AL: "Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population."</p> <p>BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 737-744, XP002256488 ISSN: 0006-4971 * page 741, right-hand column, last paragraph * page 742, right-hand column, paragraph 1</p>	1-3,7,27
X	<p>CHOPRA R ET AL: "Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study."</p> <p>BRITISH JOURNAL OF HAEMATOLOGY, vol. 111, no. 4, December 2000 (2000-12), pages 1122-1129, XP002256489 ISSN: 0007-1048 * page 1128, left-hand column, last paragraph * * page 1128, right-hand column, last paragraph *</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-3,7,27

## INTERNATIONAL SEARCH REPORT

International Application No

PC P 03/05753

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 48843 A (BURCOGLU ARSINUR) 5 November 1998 (1998-11-05) claim 1 page 14, paragraph 1 ---	1-3,7
Y	SCHROEDER HENNING: "Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity." JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 47, no. 3, 1995, pages 250-252, XP008022870 ISSN: 0022-3573 * page 251, left-hand column, last paragraph to right-hand column; first paragraph * * page 251, right-hand column, last paragraph * -----	1-28

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/05753

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Present claims 1 - 6, 8 - 25, 27 and 28 relate to an extremely large number of possible compounds ("protective oligodeoxyribonucleotide"). Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the use of defibrotide for the treatment of patients conditioned with chemotherapy.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/05753

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9848843	A	05-11-1998	AU 754242 B2	07-11-2002
			AU 7160998 A	24-11-1998
			CA 2259041 A1	05-11-1998
			EP 1202750 A1	08-05-2002
			WO 9848843 A1	05-11-1998
			US 2003013669 A1	16-01-2003

**THIS PAGE BLANK (USPTO)**